Meeting
2022 ASCO Annual Meeting
AMBER parts 1c and 1e: A phase 1 study of cobolimab plus dostarlimab in patients (pts) with advanced/metastatic melanoma.
Authors
Antoni Ribas
University of California Los Angeles, Los Angeles, CA
Antoni Ribas , Zeynep Eroglu , Jose Manuel Manuel Trigo Perez , Brian Di Pace , Tianli Wang , Srimoyee Ghosh , Arindam Dhar , Theo Borgovan , Angela Waszak , Diwakar Davar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02817633
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9513)
DOI
10.1200/JCO.2022.40.16_suppl.9513
Abstract #
9513
Poster Bd #
107
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 1/2 study of retifanlimab (INCMGA00012, Anti–PD-1), INCAGN02385 (Anti–LAG-3), and INCAGN02390 (Anti–TIM-3) combination therapy in patients (Pts) with advanced solid tumors.
First Author: Omid Hamid
Poster
2023 ASCO Annual Meeting
Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab.
First Author: Martin Reck
Poster
2022 ASCO Annual Meeting
A phase 1 multiple-ascending dose study to evaluate the safety and tolerability of XmAb23104 (PD-1 x ICOS) in subjects with selected advanced solid tumors (DUET-3).
First Author: Mehmet Akce
Poster
2020 ASCO Virtual Scientific Program
Controlled IL-12 in combination with a PD-1 inhibitor subjects with recurrent glioblastoma.
First Author: E. Antonio Chiocca